| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |